Guardant Health, Inc. (NASDAQ:GH – Get Rating) CEO Amirali Talasaz purchased 40,000 shares of the business’s stock in a transaction that occurred on Monday, March 13th. The stock was bought at an average price of $25.66 per share, with a total value of $1,026,400.00. Following the completion of the purchase, the chief executive officer now owns 1,893,845 shares of the company’s stock, valued at approximately $48,596,062.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Guardant Health Stock Performance
NASDAQ GH opened at $28.26 on Friday. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -4.42 and a beta of 0.86. Guardant Health, Inc. has a twelve month low of $24.20 and a twelve month high of $77.72. The stock has a fifty day simple moving average of $29.55 and a 200 day simple moving average of $40.91. The company has a quick ratio of 5.90, a current ratio of 6.17 and a debt-to-equity ratio of 18.90.
Institutional Trading of Guardant Health
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Guardant Health by 0.8% in the third quarter. Vanguard Group Inc. now owns 8,915,566 shares of the company’s stock valued at $479,925,000 after purchasing an additional 74,247 shares during the period. Capital International Investors increased its holdings in Guardant Health by 71.0% in the first quarter. Capital International Investors now owns 5,081,624 shares of the company’s stock valued at $336,607,000 after purchasing an additional 2,110,240 shares during the period. Clearbridge Investments LLC increased its holdings in Guardant Health by 8.0% in the first quarter. Clearbridge Investments LLC now owns 3,354,024 shares of the company’s stock valued at $222,171,000 after purchasing an additional 247,486 shares during the period. Alliancebernstein L.P. grew its holdings in Guardant Health by 243.3% during the 4th quarter. Alliancebernstein L.P. now owns 2,515,992 shares of the company’s stock worth $68,435,000 after acquiring an additional 1,783,131 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 6.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,702,980 shares of the company’s stock worth $46,322,000 after acquiring an additional 108,381 shares during the period. 90.43% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.